Group 1 - The stock price of Jinxin Reproductive Medicine (01951) increased by 1.99% to HKD 2.56, with a trading volume of HKD 66.02 million [2][5] - The National Medical Security Work Conference held on December 13 emphasized the need to adapt to population development strategies and promote the development of maternity insurance and long-term care insurance [2][5] - By 2025, all 31 provinces and regions, including Xinjiang Production and Construction Corps, are expected to include eligible assisted reproductive projects in medical insurance, with 7 provinces achieving full coverage of hospitalization costs for childbirth [2][5] Group 2 - Jinxin Reproductive Medicine announced a share buyback plan with a total price of no less than HKD 100 million, having repurchased 23.224 million shares for HKD 57.717 million last week [2][5] - As of now, the company has completed the buyback of 30.946 million shares this month, totaling HKD 77.515 million [2][5] - The company aims to focus on improving operational performance and enhancing intrinsic value to create sustainable returns for shareholders [2][5]
锦欣生殖盘中涨超3% 上周公司回购股份2322.4万股